{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T13:13:04Z","timestamp":1775826784535,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004844","name":"National Cheng Kung University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004844","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004738","name":"E-Da Hospital","doi-asserted-by":"publisher","award":["B105-F0001J"],"award-info":[{"award-number":["B105-F0001J"]}],"id":[{"id":"10.13039\/501100004738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.lungcan.2018.09.002","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T13:09:40Z","timestamp":1536325780000},"page":"35-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6380-3527","authenticated-orcid":false,"given":"Yu-Feng","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Yao","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9116-8383","authenticated-orcid":false,"given":"Chao-Chun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Hsiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu-Chou","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yau-Lin","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Chung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ting","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2018.09.002_bib0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejcts.2009.05.038","article-title":"Thymoma and thymic carcinoma","volume":"37","author":"Venuta","year":"2010","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0010","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0015","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jtcvs.2005.07.026","article-title":"Predictors of recurrence in thymic tumors: importance of invasion, World Health Organization histology, and size","volume":"130","author":"Wright","year":"2005","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0020","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/JTO.0000000000000128","article-title":"Thymic carcinoma: a cohort study of patients from the European society of thoracic surgeons database","volume":"9","author":"Ruffini","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.lungcan.2013.11.015","article-title":"Outcome of surgically resected thymic carcinoma: a multicenter experience","volume":"83","author":"Filosso","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2018.09.002_bib0030","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1200\/JCO.2004.10.113","article-title":"Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis","volume":"22","author":"Strobel","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0035","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/jso.20671","article-title":"Outcome of surgical treatment for recurrent thymic epithelial tumors with reference to world health organization histologic classification system","volume":"95","author":"Okumura","year":"2007","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0040","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0045","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/ejcts\/ezv086","article-title":"Surgical treatment of recurrent thymoma: is it worthwhile?","volume":"49","author":"Marulli","year":"2016","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168215","article-title":"Octreotide LAR and prednisone as neoadjuvant treatment in patients with primary or locally recurrent unresectable thymic tumors: a phase II study","volume":"11","author":"Kirzinger","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2018.09.002_bib0055","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jtcvs.2013.08.061","article-title":"Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial","volume":"147","author":"Korst","year":"2014","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0060","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1600-065X.2008.00610.x","article-title":"Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape","volume":"222","author":"Katz","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0065","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/bjc.2011.513","article-title":"Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer","volume":"106","author":"Ferdinande","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2018.09.002_bib0070","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-04-2671","article-title":"Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells","volume":"11","author":"Okamoto","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0075","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00432-008-0395-1","article-title":"Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma","volume":"134","author":"Pan","year":"2008","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0080","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00277-010-1093-z","article-title":"Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"90","author":"Ninomiya","year":"2011","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0085","doi-asserted-by":"crossref","first-page":"e2278","DOI":"10.1097\/MD.0000000000002278","article-title":"Behind and beyond the masaoka staging: a 25-Year follow-up study of tumor recurrence in completely resected thymic epithelial tumors in a single institution","volume":"94","author":"Tseng","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.lungcan.2018.09.002_bib0090","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1080\/15384047.2016.1235666","article-title":"Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse","volume":"17","author":"Nardone","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0095","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7150\/jca.14549","article-title":"PD-L1 expression is associated with tumor FOXP3(+) regulatory T-Cell infiltration of breast cancer and poor prognosis of patient","volume":"7","author":"Li","year":"2016","journal-title":"J. Cancer"},{"key":"10.1016\/j.lungcan.2018.09.002_bib0100","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.amjoto.2014.08.009","article-title":"FoxP3 and indoleamine 2,3-dioxygenase immunoreactivity in sentinel nodes from melanoma patients","volume":"35","author":"Ryan","year":"2014","journal-title":"Am. J. Otolaryngol."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0105","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1089\/thy.2013.0423","article-title":"Expression of indoleamine 2,3-dioxygenase and infiltration of FOXP3+ regulatory T cells are associated with aggressive features of papillary thyroid microcarcinoma","volume":"24","author":"Ryu","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.lungcan.2018.09.002_bib0110","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.1349-7006.2007.00470.x","article-title":"Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer","volume":"98","author":"Nakamura","year":"2007","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0115","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/annonc\/mdp056","article-title":"Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK\/T-cell lymphoma","volume":"20","author":"Kim","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/bjc.2012.524","article-title":"Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer","volume":"108","author":"West","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2018.09.002_bib0125","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1186\/s12885-016-2419-6","article-title":"Foxp3 overexpression in tumor cells predicts poor survival in oral squamous cell carcinoma","volume":"16","author":"Song","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2018.09.002_bib0130","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.2008.18.7229","article-title":"Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer","volume":"27","author":"Salama","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mpo.1154","article-title":"Response evaluation criteria in solid tumors (RECIST): new guidelines","volume":"37","author":"Tsuchida","year":"2001","journal-title":"Med. Pediatr. Oncol."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0140","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2018.09.002_bib0145","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.humpath.2016.09.023","article-title":"PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus","volume":"60","author":"Marchevsky","year":"2017","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0150","doi-asserted-by":"crossref","DOI":"10.1038\/modpathol.2017.6","article-title":"Expression of PD-1 and PD-L1 in thymic epithelial neoplasms","author":"Weissferdt","year":"2017","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0155","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2015.03.003","article-title":"Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma","volume":"88","author":"Katsuya","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2018.09.002_bib0160","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse high intensity PD-L1 staining in thymic epithelial tumors","volume":"10","author":"Padda","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0165","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0170","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0175","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.athoracsur.2015.10.044","article-title":"Clinicopathologic and prognostic implications of programmed death ligand 1 expression in Thymoma","volume":"101","author":"Yokoyama","year":"2016","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0180","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1158\/1078-0432.CCR-16-0434","article-title":"Prognostic value of programmed death ligand 1 and programmed death 1 expression in Thymic Carcinoma","volume":"22","author":"Yokoyama","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0185","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0190","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with Anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0195","first-page":"3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"2077","author":"Cho","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0200","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-Positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0205","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/ejcts\/ezu277","article-title":"A meta-analysis of debulking surgery versus surgical biopsy for unresectable thymoma","volume":"47","author":"Hamaji","year":"2015","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0210","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejcts.2009.02.019","article-title":"Early Masaoka stage and complete resection is important for prognosis of thymic carcinoma: a 20-year experience at a single institution","volume":"36","author":"Lee","year":"2009","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0215","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1007\/s00268-014-2492-4","article-title":"Prognostic factors of patients with thymic carcinoma after surgery: a retrospective analysis of 58 cases","volume":"38","author":"Wang","year":"2014","journal-title":"World J. Surg."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0220","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.ejcts.2009.11.001","article-title":"Predictors of survival in patients with locally advanced thymoma and thymic carcinoma (Masaoka stages III and IVa)","volume":"37","author":"Cardillo","year":"2010","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0225","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.4049\/jimmunol.1003797","article-title":"Functional plasticity of antigen-specific regulatory T cells in context of tumor","volume":"186","author":"Addey","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0230","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.molmed.2012.06.001","article-title":"Functional stability of Foxp3+ regulatory T cells","volume":"18","author":"da Silva Martins","year":"2012","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0235","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.immuni.2013.01.013","article-title":"An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos","volume":"38","author":"Sharma","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.lungcan.2018.09.002_bib0240","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.immuni.2010.11.022","article-title":"Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice","volume":"33","author":"Sharma","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.lungcan.2018.09.002_bib0245","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10549-010-0987-8","article-title":"An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer","volume":"127","author":"Mahmoud","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0250","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2010.30.5037","article-title":"Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer","volume":"29","author":"Mahmoud","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0255","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/08820130600745430","article-title":"Hurdles to lymphocyte trafficking in the tumor microenvironment: implications for effective immunotherapy","volume":"35","author":"Fisher","year":"2006","journal-title":"Immunol. Invest."},{"key":"10.1016\/j.lungcan.2018.09.002_bib0260","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nri2156","article-title":"Getting to the site of inflammation: the leukocyte adhesion cascade updated","volume":"7","author":"Ley","year":"2007","journal-title":"Nat. Rev. Immunol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218305476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218305476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T21:29:05Z","timestamp":1540502945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500218305476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":52,"alternative-id":["S0169500218305476"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.09.002","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}